Qube Research & Technologies (QRT)
PTGX icon

Qube Research & Technologies (QRT)’s Protagonist Therapeutics PTGX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-153,876
Closed -$13.4M – 3997
2025
Q4 		$13.4M Buy
+153,876
New +$12.6M 0.01% 1145
2025
Q3 		– Sell
-68,983
Closed -$3.81M – 3873
2025
Q2 		$3.81M Sell
68,983
-274,428
-80% -$13.2M ﹤0.01% 1864
2025
Q1 		$16.6M Buy
343,411
+31,092
+10% +$1.3M 0.02% 840
2024
Q4 		$12.1M Sell
312,319
-10,670
-3% -$465K 0.02% 985
2024
Q3 		$14.5M Sell
322,989
-130,163
-29% -$5.26M 0.02% 819
2024
Q2 		$15.7M Buy
453,152
+390,997
+629% +$11.5M 0.02% 719
2024
Q1 		$1.8M Buy
+62,155
New +$1.69M ﹤0.01% 1823
2023
Q4 		– Sell
-91,735
Closed -$1.53M – 4657
2023
Q3 		$1.53M Buy
+91,735
New +$1.78M ﹤0.01% 1525
2023
Q1 		– Sell
-135,706
Closed -$1.48M – 2929
2022
Q4 		$1.48M Buy
135,706
+44,430
+49% +$375K 0.01% 1057
2022
Q3 		$769K Buy
+91,276
New +$864K ﹤0.01% 1301
2021
Q2 		– Sell
-13,465
Closed -$349K – 2698
2021
Q1 		$349K Buy
+13,465
New +$341K 0.01% 1377

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PTGX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 153,876 shares — an estimated $13.4M sold.

Qube Research & Technologies (QRT) first reported a position in PTGX in Q1 2021 and held it in 11 quarters. The position peaked at $16.6M in Q1 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 153,876 Protagonist Therapeutics shares in Q1 2026, an estimated $13.4M.
  • Qube Research & Technologies (QRT) first reported a position in Protagonist Therapeutics in Q1 2021 and held it in 11 quarters.
  • Qube Research & Technologies (QRT)'s Protagonist Therapeutics position peaked at $16.6M in Q1 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.